文献速递眼底病与葡萄膜炎

地塞米松玻璃体内植入剂治疗孔源性视网膜脱离修复术后顽固性黄斑水肿

DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF RECALCITRANT MACULAR EDEMA AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR.
PubMed 文献 · Retina · 2018-01-01

一项两中心回顾性病历复习纳入17例(17眼)孔源性视网膜脱离修复术后顽固性黄斑水肿患者,接受0.7 mg地塞米松玻璃体内植入剂(Ozurdex)单次或多次注射。术后1个月和3个月最佳矫正视力显著改善(P<0.001和P=0.01),黄斑中心凹厚度和黄斑立方体体积在1个月和3个月显著下降。全部患者3个月时黄斑水肿复发需再次治疗,未发生视网膜脱离或眼内炎等不良事件。

要点

  • 17眼中12眼曾行玻璃体内曲安奈德注射,黄斑水肿仍持续。
  • 1个月最佳矫正视力改善P<0.001,3个月P=0.01;黄斑中心凹厚度由505 μm降至290 μm(P=0.013)。
  • 全部患者3个月时黄斑水肿复发需再次治疗,平均植入4次(范围1–14次)。

核心结论

  • 孔源性视网膜脱离成功修复术后出现的黄斑水肿可呈慢性、顽固性,地塞米松玻璃体内植入剂可能安全有效地治疗此类黄斑水肿。

研究设计与样本

  • 两中心回顾性病历复习,纳入17例连续患者(17眼),均为孔源性视网膜脱离修复术后顽固性黄斑水肿,接受单次或多次0.7 mg地塞米松玻璃体内植入剂(Ozurdex;Allergan公司)注射。
  • 平均年龄67岁(范围51–78岁)。

主要发现

  • 全部17例患者此前接受过局部治疗,其中12例曾行玻璃体内曲安奈德注射后黄斑水肿仍持续。
  • 患眼基线平均最佳矫正视力为20/100(logMAR 0.75;范围0.18–1.3,±0.37),1个月(P<0.001)和3个月(P=0.01)最佳矫正视力较基线有统计学显著改善。
  • 基线平均黄斑中心凹厚度505 μm、平均黄斑立方体体积10.62 mm,1个月时黄斑中心凹厚度由505 μm降至290 μm(P=0.013)、黄斑立方体体积由10.62 mm降至9.13 mm(P<0.0001),3个月时二者下降亦有统计学意义(P=0.01)。
  • 全部患者3个月时黄斑水肿复发并需再次治疗,平均植入次数4次(范围1–14次)。
  • 未发生视网膜脱离或眼内炎等不良事件;2例患者眼压升高,经局部药物治疗得到控制。

关键数值与推荐

  • 地塞米松植入剂剂量为0.7 mg(Ozurdex;Allergan公司),单次或多次注射。
  • 1个月时黄斑中心凹厚度由505 μm降至290 μm(P=0.013),黄斑立方体体积由10.62 mm降至9.13 mm(P<0.0001)。
  • 最佳矫正视力改善:1个月P<0.001,3个月P=0.01。

临床怎么用

  • 作者认为孔源性视网膜脱离成功修复术后发生的黄斑水肿可呈慢性、顽固性,地塞米松玻璃体内植入剂可能安全有效地治疗此类黄斑水肿。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the efficacy of the intravitreal dexamethasone implant as the treatment for recalcitrant macular edema after successful rhegmatogenous retinal detachment repair. METHODS: A retrospective review of the medical records was performed on 17 consecutive patients (17 eyes) with recalcitrant macular edema associated with rhegmatogenous retinal detachment repair who were treated with a single or multiple injections of an intravitreal dexamethasone 0.7-mg implant (Ozurdex; Allergan Inc) at two centers. Main outcomes of the study were change in logarithm of the minimum angle of resolution visual acuity, measurement of central foveal thickness, and macular cube volume as measured by spectral domain optical coherence tomography and frequency of complications. RESULTS: The mean age was 67 years (range, 51-78 years). All 17 patients received previous topical therapy and 12 of them had previous administration of intravitreal triamcinolone with persistence of macular edema. Baseline mean best-corrected visual acuity was 20/100 (logarithm of the minimum angle of resolution 0.75; range, 0.18-1.3 ±0.37) in the affected eyes. There was a statistically significant improvement in best-corrected visual acuity at 1 month (P < 0.001) and 3 months (P = 0.01). Mean baseline central foveal thickness was 505 μm, and mean macular cube volume was 10.62 mm. There was a statistically significant decrease in central foveal thickness and macular cube volume at 1 month (505-290 μm, P = 0.013 and 10.62-9.13 mm, P < 0.0001) and 3 months (P = 0.01). All patients developed recurrence of macular edema at 3 months, which required retreatment. The average number of implants was 4 (range, 1-14). No adverse effects such as retinal detachment or endophthalmitis occurred. Two patients experienced an increase in intraocular pressure that was controlled with topical therapy. CONCLUSION: Macular edema that occurs in eyes after successful repair of rhegmatogenous retinal detachment can be chronic and recalcitrant, and may be successfully and safely treated with the dexamethasone intravitreal implant.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Thanos A, Todorich B, Yonekawa Y, et al. DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF RECALCITRANT MACULAR EDEMA AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR. Retina. 2018. PMID: 28622270. doi:10.1097/IAE.0000000000001720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。